Literature DB >> 21851379

The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.

Nicholas G Martin1, Ka Wah Li, Heather Murray, Wendy Putt, Chris J Packard, Steve E Humphries.   

Abstract

AIM: To determine whether the SNP rs4149056 in SLCO1B1 alters the pharmacodynamics of pravastatin.
METHODS: rs4149056 was genotyped in 626 pravastatin-treated participants in the WOSCOPS trial and the response after 1 year of treatment was compared between the different genotypes.
RESULTS: Pravastatin reduced serum LDL cholesterol by 22.2% in TT homozygotes, by 22.2% in TC heterozygotes and by 17.7% in CC homozygotes (TT + TC vs. CC P value 0.33). There were no significant differences in the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin between the genotypes.
CONCLUSION: The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21851379      PMCID: PMC3269589          DOI: 10.1111/j.1365-2125.2011.04090.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study.

Authors:  Francesco Zito; Gordon D O Lowe; Ann Rumley; Alex D McMahon; Steve E Humphries
Journal:  Atherosclerosis       Date:  2002-11       Impact factor: 5.162

2.  Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.

Authors:  Hiroshi Takane; Masanori Miyata; Naoto Burioka; Chiaki Shigemasa; Eiji Shimizu; Kenji Otsubo; Ichiro Ieiri
Journal:  J Hum Genet       Date:  2006-08-18       Impact factor: 3.172

3.  SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Authors:  Wei Zhang; Bi-Lian Chen; Vural Ozdemir; Yi-Jing He; Gan Zhou; Dao-Di Peng; Sheng Deng; Qi-Ying Xie; Wei Xie; Lin-Yong Xu; Lian-Ci Wang; Lan Fan; An Wang; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

4.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

Authors:  Marja K Pasanen; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Pharmacogenet Genomics       Date:  2006-12       Impact factor: 2.089

5.  Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Authors:  Michael Igel; Katja A Arnold; Mikko Niemi; Ute Hofmann; Matthias Schwab; Dieter Lütjohann; Klaus von Bergmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2006-04-11       Impact factor: 6.875

Review 6.  The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

Authors:  S P R Romaine; K M Bailey; A S Hall; A J Balmforth
Journal:  Pharmacogenomics J       Date:  2009-11-03       Impact factor: 3.550

Review 7.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

8.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

9.  Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose.

Authors:  I N Day; S E Humphries
Journal:  Anal Biochem       Date:  1994-11-01       Impact factor: 3.365

10.  Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.

Authors:  Takao Watanabe; Hiroyuki Kusuhara; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2008-11-10       Impact factor: 4.030

View more
  7 in total

1.  Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.

Authors:  Ruth Cano-Corres; Beatriz Candás-Estébanez; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Xavier Pintó; Pedro Alía-Ramos
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

2.  Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Authors:  Jonathan B Wagner; Melissa Ruggiero; J Steven Leeder; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2020-09-05       Impact factor: 3.922

3.  Genetic contribution to lipid target achievement with statin therapy: a prospective study.

Authors:  Cristina Ruiz-Iruela; Beatriz Candás-Estébanez; Xavier Pintó-Sala; Neus Baena-Díez; Assumpta Caixàs-Pedragós; Roser Güell-Miró; Rosa Navarro-Badal; Pilar Calmarza; Jose Luis Puzo-Foncilla; Pedro Alía-Ramos; Ariadna Padró-Miquel
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.550

4.  Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.

Authors:  Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2013-05       Impact factor: 2.089

Review 5.  Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.

Authors:  Stella Aslibekyan; Robert J Straka; Marguerite R Irvin; Steven A Claas; Donna K Arnett
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-03

6.  Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.

Authors:  Jonathan B Wagner; Susan Abdel-Rahman; Andrea Gaedigk; Roger Gaedigk; Geetha Raghuveer; Vincent S Staggs; Leon Van Haandel; J Steven Leeder
Journal:  Clin Transl Sci       Date:  2020-03-09       Impact factor: 4.689

Review 7.  Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.

Authors:  Danielle Johnson; Dyfrig Hughes; Munir Pirmohamed; Andrea Jorgensen
Journal:  J Pers Med       Date:  2019-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.